This study aims to determine whether isobaric ropivacaine is more suitable than isobaric bupivacaine for spinal anesthesia in outpatient total hip arthroplasty (THA). The study will evaluate whether ropivacaine allows faster recovery of sensory and motor function while still providing adequate surgical anesthesia and postoperative pain control. Additional aims are to assess the effects of the anesthetic technique on same-day discharge rates, postoperative recovery, urinary retention, opioid consumption, and patient satisfaction after outpatient THA.
18 - 80 years of age
Scheduled for a primary elective total hip arthroplasty
Patient must be a candidate for same day discharge
Informed consent understood and signed
Scheduled bilateral THA
Contraindication to or failed spinal anesthesia
Allergy or contraindication to NSAIDs (e.g. chronic kidney disease)
Diabetes requiring insulin medication
Parallel
Spinal Anesthesia with Ropivacaine 15 mg (5 mg/ml)
DrugPatients receive spinal anesthesia with intrathecal ropivacaine
Spinal Anesthesia with Bupivacaine 11 mg (5 mg/ml)
DrugPatients receive spinal anesthesia with intrathecal bupivacaine
Return of Sensory and Motor Function
Numeric Rating Scale (NRS) for Postoperative Pain
Pain intensity score assessed using the Numeric Rating Scale (NRS) for Pain (range 0 to 10, where 0 indicates no pain and 10 indicates worst possible pain; higher scores indicate worse pain outcomes).
Urinary retention
Post-operative nausea and vomiting
Postoperative opioid consumption in morphine milligram equivalents (MME)
Click on the lead sponsor to view all of their trials.
University of Turku
Lead sponsor
Turku University Hospital
Collaborator
This trial is not recruiting at the moment. You can still explore other options:
